
CMEA Ventures
Description
CMEA Ventures, also known as CMEA Capital, was a prominent venture capital firm based in San Francisco, California, specializing in investments across high technology, life sciences, and alternative energy sectors. Founded in 1989, the firm established itself as an early and significant player in the venture capital landscape. However, it is crucial to note that CMEA Ventures is no longer an active investment firm, having ceased new investments and effectively closed its operations after its final fund.
Throughout its operational history, CMEA Ventures managed a substantial capital base, totaling approximately $1.2 billion across seven distinct funds. The firm's investment strategy typically focused on early-stage companies, providing significant capital to fuel their growth and innovation. Historically, CMEA Ventures' initial cheque sizes ranged from $5 million to $15 million, targeting companies with disruptive technologies and strong market potential within its core sectors. This approach allowed them to support a diverse portfolio of startups, from nascent biotech firms to emerging clean energy ventures.
Before its closure, CMEA Ventures built an impressive track record, marked by a substantial number of successful exits. The firm recorded over 100 exits, demonstrating its ability to identify and nurture promising companies to successful liquidity events, including IPOs and acquisitions. Its portfolio included notable companies across various technology and life science domains, contributing significantly to innovation in Silicon Valley and beyond. While its active investment period has concluded, CMEA Ventures' legacy remains in the companies it helped build and the capital it deployed over more than two decades.
Investor Profile
CMEA Ventures has backed more than 70 startups, with 0 new investments in the last 12 months alone. The firm has led 8 rounds, about 11% of its total and boasts 33 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in United States, Canada, Singapore.
- Strong thematic focus on Biotechnology, Health Care, Software.
- Typical check size: $5M – $15M.
Stage Focus
- Series B (27%)
- Series C (26%)
- Series A (19%)
- Series Unknown (14%)
- Series D (6%)
- Private Equity (4%)
- Debt Financing (3%)
- Series E (1%)
Country Focus
- United States (91%)
- Canada (4%)
- Singapore (4%)
Industry Focus
- Biotechnology
- Health Care
- Software
- Pharmaceutical
- Consulting
- Information Technology
- Medical
- Therapeutics
- Biopharma
- Manufacturing
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.